IQVIA Reports Revenue Growth to $3.74 Billion in Q1, Beats Forecasts

IQVIA Holdings Inc. (NYSE: IQV) has recently disclosed its financial outcomes for the first quarter of 2024, showcasing a solid performance across its diverse service segments. The company reported a revenue of $3,737 million, marking a 2.3 percent increase on a reported basis and a 2.9 percent increase at constant currency compared to the same period in 2023.

Particularly noteworthy was the Research & Development Solutions (R&DS) segment, which saw a revenue increase of 3.4 percent on a reported basis and 3.8 percent at constant currency. This segment, excluding the impact of pass-throughs, experienced a robust growth of 6.9 percent on a reported basis.

The company’s contracted backlog in R&DS stood at an impressive $30.1 billion, up by 7.9 percent year-over-year. Approximately $7.7 billion of this backlog is expected to convert to revenue in the next twelve months. The first-quarter book-to-bill ratio was a healthy 1.23x, signaling strong future revenue potential.

IQVIA Holdings Beats EPS and Revenue Expectations in Q1

IQVIA’s financial position remains strong, with cash and cash equivalents totaling $1.4 billion as of March 31, 2024. The company’s net debt was $12.09 billion, resulting in a net leverage ratio of 3.38x trailing twelve-month Adjusted EBITDA.

For the first quarter, IQVIA generated an operating cash flow of $522 million and a free cash flow of $377 million. These figures underscore the company’s robust financial health and ability to generate significant cash flows, further solidifying its position as a leader in providing advanced analytics, technology solutions, and clinical research services to the life sciences industry.

Analysts had projected an EPS of $2.48, whereas the company reported an adjusted diluted EPS of $2.54, slightly outperforming the expectations.

However, the revenue of $3.74 billion comfortably exceeded the anticipated $3.7 billion, indicating a stronger-than-expected top-line growth. This performance is particularly commendable given the challenging global economic environment and underscores IQVIA’s operational resilience and the effectiveness of its business strategy.

Join our Telegram group and never miss a breaking story.

IQVIA Expects Full Year Revenue to be Between $15.32 to $15.57 Billion

IQVIA has reaffirmed its full-year 2024 guidance, reflecting confidence in its business outlook despite the ongoing global uncertainties.

The company expects full-year revenue to be in the range of $15.325 billion to $15.575 billion on a reported basis, considering the $75 million impact of the strengthening US dollar. This guidance suggests a growth rate of 2.3 to 3.9 percent, with a foreign exchange headwind of approximately 100 basis points.

Furthermore, IQVIA anticipates its full-year Adjusted EBITDA to be between $3,700 million and $3,800 million, representing a growth of 3.7 to 6.5 percent.

The Adjusted Diluted EPS guidance is set at $10.95 to $11.25, indicating a year-over-year increase of 7.4 to 10.3 percent.

Disclaimer: The author does not hold or have a position in any securities discussed in the article.